Mutations in the nef and vif genes associated with progression to AIDS in elite controller and slow-progressor Patients

Journal of Medical Virology

Volumn 85, Issue 4, 2013, Pages 563-574

  Cruz, Nadia V G ^a,b   Amorim, Raquel ^a   Oliveira, Fátima E ^b   Speranza, Francisco A C ^b   Costa, Luciana J ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Laboratory of Virology   (Brazil)

Author keywords

Elite controllers; HIV; Nef; Progression to AIDS; Vif

Indexed keywords

NEF PROTEIN; VIF PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CARBOXY TERMINAL SEQUENCE; CODON; DISEASE COURSE; DNA SYNTHESIS; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LOSS OF FUNCTION MUTATION; PROTEIN EXPRESSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DISEASE PROGRESSION; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; MUTATION; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84873941169     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23512     Document Type: Article

References (57)

1. Aguiar RS, Peterlin BM. 2008. APOBEC3 proteins and reverse transcription. Virus Res 134: 74-85.
2. Alexander L, Aquino-DeJesus MJ, Chan M, Andiman WA. 2002. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child. J Virol 76: 10533-10539.
3. Bentham MMS, Harris M. 2003. The di-leucine motif in the cytoplasmic tail of CD4 is not required for binding to human immunodeficiency virus type 1 Nef, but is critical for CD4 down-modulation. J Gen Virol 84: 2705-2713.
4. Blagoveshchenskaya ADTL, Feliciangeli SF, Hung CH, Thomas G. 2002. HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. Cell 111: 853-866.
5. Carl S, Greenough TC, Krumbiegel M, Greenberg M, Skowronski J, Sullivan JL, Kirchhoff F. 2001. Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol 75: 3657-3665.
6. Chaudhry A, Verghese DA, Das SR, Jameel S, George A, Bal V, Mayor S, Rath S. 2009. HIV-1 Nef promotes endocytosis of cell surface MHC class II molecules via a constitutive pathway. J Immunol 183: 2415-2424.
7. Chen YL, Trono D, Camaur D. 1998. The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity. J Virol 72: 3178-3184.
8. Cheng-Mayer C, Iannello P, Shaw K, Luciw PA, Levy JA. 1989. Differential effects of nef on HIV replication: Implications for viral pathogenesis in the host. Science 246: 1629-1632.
9. Chowers MY, Pandori MW, Spina CA, Richman DD, Guatelli JC. 1995. The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology 212: 451-457.
10. Costa LJ, Chen N, Lopes A, Aguiar RS, Tanuri A, Plemenitas A, Peterlin BM. 2006. Interactions between Nef and AIP1 proliferate multivesicular bodies and facilitate egress of HIV-1. Retrovirol 3: 33.
11. Costa LJ, Zheng YH, Sabotic J, Mak J, Fackler OT, Peterlin BM. 2004. Nef binds p6* in GagPol during replication of human immunodeficiency virus type 1. J Virol 78: 5311-5323.
12. Couto-Fernandez JC, Eyer-Silva WA, Guimarães ML, Chequer-Fernandez SL, Grinsztejn B, Delaporte E, Peeters M, Morgado MG. 2006. Phylogenetic analysis of Brazilian HIV type 1 subtype D strains: Tracing the origin of this subtype in Brazil. AIDS Res 22: 207-211.
13. Crotti A, Neri F, Corti D, Ghezzi S, Heltai S, Baur A, Poli G, Santagostino E, Vicenzi E. 2006. Nef alleles from human immunodeficiency virus type 1-infected long-term-nonprogressor hemophiliacs with or without late disease progression are defective in enhancing virus replication and CD4 down-regulation. J Virol 80: 10663-10674.
14. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258: 1938-1941.
15. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, Lawson VA, Crowe S, Maerz A, Sonza S, Learmont J, Sullivan JS, Cunningham A, Dwyer D, Dowton D, Mills J. 1995. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270: 988-991.
16. Fackler OTKH. 2006. Interactions of human retroviruses with the host cell cytoskeleton. Curr Opin Microbiol 9: 409-415.
17. Farrow MA, Somasundaran M, Zhang C, Gabuzda D, Sullivan JL, Greenough TC. 2005. Nuclear localization of HIV type 1 Vif isolated from a long-term asymptomatic individual and potential role in virus attenuation. AIDS Res 21: 565-574.
18. Geyer M, Fackler OT, Peterlin BM. 2001. Structure-function relationships in HIV-1 Nef. EMBO Rep 2: 580-585.
19. Goldsmith MA, Warmerdam MT, Atchison RE, Miller MD, Greene WC. 1995. Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef. J Virol 69: 4112-4121.
20. Greenberg MEIA, Skowronski J. 1998. The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. EMBO J 17: 2777-2789.
21. Hammes SR, Dixon EP, Malim MH, Cullen BR, Greene WC. 1989. Nef protein of human immunodeficiency virus type 1: Evidence against its role as a transcriptional inhibitor. Proc Natl Acad Sci USA 86: 9549-9553.
22. Huang Y, Zhang L, Ho DD. 1995. Biological characterization of nef in long-term survivors of human immunodeficiency virus type 1 infection. J Virol 69: 8142-8146.
23. Huang Y, Zhang L, Ho DD. 1998. Characterization of gag and pol sequences from long-term survivors of human immunodeficiency virus type 1 infection. Virology 240: 36-49.
24. Ibe S, Shigemi U, Sawaki K, Fujisaki S, Hattori J, Yokomaku Y, Mamiya N, Hamaguchi M, Kaneda T. 2008. Analysis of near full-length genomic sequences of drug-resistant HIV-1 spreading among therapy-naïve individuals in Nagoya, Japan: Amino acid mutations associated with viral replication activity. AIDS Res 24: 1121-1125.
25. Jere A, Fujita M, Adachi A, Nomaguchi M. 2010. Role of HIV-1 Nef protein for virus replication in vitro. Microbes Infect 12: 65-70.
26. Kim S, Ikeuchi K, Byrn R, Groopman J, Baltimore D. 1989. Lack of a negative influence on viral growth by the nef gene of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 86: 9544-9548.
27. Kirchhoff F, Easterbrook PJ, Douglas N, Troop M, Greenough TC, Weber J, Carl S, Sullivan JL, Daniels RS. 1999. Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J Virol 73: 5497-5508.
28. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. 1995. Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 332: 228-232.
29. Kotov AZJ, Flicker P, Aiken C. 1999. Association of Nef with the human immunodeficiency virus type 1 core. J Virol 73: 8824-8830.
30. Krautkramer E, Giese SI, Gasteier JE, Muranyi W, Fackler OT. 2004. Human immunodeficiency virus type 1 Nef activates p21-activated kinase via recruitment into lipid rafts. J Virol 78: 4085-4097.
31. Kwak YT, Raney A, Kuo LS, Denial SJ, Temple BR, Garcia JV, Foster JL. 2010. Self-association of the Lentivirus protein, Nef. Retrovirology 7: 77.
32. Lama J, MA Trono D. 1999. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol 9: 622-631.
33. Langford SE, Ananworanich J, Cooper DA. 2007. Predictors of disease progression in HIV infection: A review. AIDS Res Ther 4: 11.
34. Mahlknecht U, Deng C, Lu MC, Greenough TC, Sullivan JL, O'Brien WA, Herbein G. 2000. Resistance to apoptosis in HIV-infected CD4+ T lymphocytes is mediated by macrophages: Role for Nef and immune activation in viral persistence. J Immunol 165: 6437-6446.
35. Mandic RFO, Geyer M, Linnemann T, Zheng YH, Peterlin BM. 2001. Negative factor from SIV binds to the catalytic subunit of the V-ATPase to internalize CD4 and to increase viral infectivity. Mol Biol Cell 12: 463-473.
36. Michael NL, Chang G, d'Arcy LA, Tseng CJ, Birx DL, Sheppard HW. 1995. Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression. J Virol 69: 6758-6769.
37. Miller MD, Warmerdam MT, Ferrell SS, Benitez R, Greene WC. 1997. Intravirion generation of the C-terminal core domain of HIV-1 Nef by the HIV-1 protease is insufficient to enhance viral infectivity. Virology 234: 215-225.
38. Miller MD, Warmerdam MT, Page KA, Feinberg MB, Greene WC. 1995. Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry. J Virol 69: 579-584.
39. Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, Pereyra F, Trocha A, Addo MM, Block BL, Rothchild AC, Baker BM, Flynn T, Schneidewind A, Li B, Wang YE, Heckerman D, Allen TM, Walker BD. 2008. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: Lack of gross genetic defects or common amino acid changes. J Virol 82: 8422-8430.
40. Mologni D, Citterio P, Menzaghi B, Zanone Poma B, Riva C, Broggini V, Sinicco A, Milazzo L, Adorni F, Rusconi S, Galli M, Riva A, Group r. 2006. Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. AIDS 20: 567-574.
41. O'Connell KA, Bailey JR, Blankson JN. 2009. Elucidating the elite: Mechanisms of control in HIV-1 infection. Trends Pharmacol Sci 30: 631-637.
42. O'Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF, Blankson JN. 2010. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol 84: 7018-7028.
43. Pandori MW, Fitch NJ, Craig HM, Richman DD, Spina CA, Guatelli JC. 1996. Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J Virol 70: 4283-4290.
44. Piguet V, Gu F, Foti M, Demaurex N, Gruenberg J, Carpentier JL, Trono D. 1999. Nef-induced CD4 degradation: A diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes. Cell 97: 63-73.
45. Poropatich K, Sullivan DJ. 2011. Human immunodeficiency virus type 1 long-term non-progressors: The viral, genetic and immunological basis for disease non-progression. J Gen Virol 92: 247-268.
46. Pushker R, Jacqué JM, Shields DC. 2010. Meta-analysis to test the association of HIV-1 nef amino acid differences and deletions with disease progression. J Virol 84: 3644-3653.
47. Rachinger A, Navis M, van Assen S, Groeneveld PH, Schuitemaker H. 2008. Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection. Clin Infect Dis 47: e86- e89.
48. Rangel HR, Garzaro D, Rodríguez AK, Ramírez AH, Ameli G, Del Rosario Gutiérrez C, Pujol FH. 2009. Deletion, insertion and stop codon mutations in vif genes of HIV-1 infecting slow progressor patients. J Infect Dev Ctries 3: 531-538.
49. Rodés B, Toro C, Paxinos E, Poveda E, Martinez-Padial M, Benito JM, Jimenez V, Wrin T, Bassani S, Soriano V. 2004. Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS 18: 1109-1116.
50. Roeth JFWM, Kasper MR, Filzen TM, Collins KL. 2004. HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail. J Cell Biol 167: 903-913.
51. Ross TM, Oran AE, Cullen BR. 1999. Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein. Curr Biol 9: 613-621.
52. Saksela K, Cheng G, Baltimore D. 1995. Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. EMBO J 14: 484-491.
53. Saksena NK, Rodes B, Wang B, Soriano V. 2007. Elite HIV controllers: Myth or reality? AIDS Rev 9: 195-207.
54. Schindler MMJ, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Müller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, Bailes E, Roques P, Sodora DL, Silvestri G, Sharp PM, Hahn BH, Kirchhoff F. 2006. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 125: 1055-1067.
55. Schorr J, Kellner R, Fackler O, Freund J, Konvalinka J, Kienzle N, Krausslich HG, Mueller-Lantzsch N, Kalbitzer HR. 1996. Specific cleavage sites of Nef proteins from human immunodeficiency virus types 1 and 2 for the viral proteases. J Virol 70: 9051-9054.
56. Tobiume M, Fujinaga K, Suzuki S, Komoto S, Mukai T, Ikuta K. 2002. Extracellular Nef protein activates signal transduction pathway from Ras to mitogen-activated protein kinase cascades that leads to activation of human immunodeficiency virus from latency. AIDS Res 18: 461-467.
57. Trible RP, Emert-Sedlak L, Wales TE, Ayyavoo V, Engen JR, Smithgall TE. 2007. Allosteric loss-of-function mutations in HIV-1 Nef from a long-term non-progressor. J Mol Biol 374: 121-129.